Rofecoxib provides relief of pain following third molar extractions

References 

1. Merck .amp; Co., Inc. Merck announces voluntary withdrawal of Vioxx. Available at: http://www.vioxx.com/rofecoxib/vioxx/consumer/voluntary_withdrawl_statement.jspAccessed August 24, 2006
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520–1528
   • MEDLINE
   • CrossRef
3. Cooper SA, Beaver WT. A model to evaluate mild analgesics in oral surgery outpatients. Clin Pharmacol Ther. 1976;20:241–250
   • MEDLINE
4. Jackson DL, Roszkowski MT, Moore PA. Management of acute postoperative pain. In:  Frost DE,  Hersh E,  Levin LM editor. Oral and maxillofacial surgery. Philadelphia: W B Saunders; 2000;p. 114–140
5. Mahmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardin PJ. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther. 1999;21:1653–1663
   • Abstract
   • Full-Text PDF (831 KB)
   • CrossRef
6. Morrison BW, Christensen S, Weiying Y, Brown J, Amlani S, Seidenberg B. Analgesic efficacy of the cyclooxygenase-2-sepcific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Therap. 1999;21(6):943–951
7. Ehlich EW, Dallob A, Lepeleire ID, Van Hecken A, Riendau D, Yaun W, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental model. Clin Pharmacol Ther. 1999;6:83–92
8. Moore PA, Nahouraii HS, Zovko J, Wisniewski SR. Dental therapeutic practice patterns in the US. II. Analgesics, corticosteroids, and antibiotics. Gen Dent. 2006;54(3):201–207
   • MEDLINE
9. Moore PA, Hersh EV. Celecoxib and rofecoxib: the role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001;132:451–456
   • MEDLINE